ÏÔ΢ÊÖÊõÖÎÁÆÖ¬·¾ÁöÐͼ¹Ëè˩ϵ×ÛºÏÕ÷µÄÁÆÐ§·ÖÎö
¡ª¡ª¸½Àý²¡Àý±¨¸æ
¡¡¡¡´Þ־ǿÐÞ²¨*Ïô¿ËïÕñÐËÂÞÌ챦¶ÎºêÓî
¡¡¡¡Ò½Ôº¼¹Ëè¼¹ÖùÉñ¾Íâ¿Æ±±¾©¡¡()
¡¡¡¡Ä¿µÄ:ͨ¹ý¶ÔÀýÖ¬·¾ÁöÐͼ¹Ëè˩ϵ×ÛºÏÕ÷ÁÙ´²Êý¾Ý·ÖÎöÆÀ¼ÛÖ¬·¾ÁöÐͼ¹Ëè˩ϵ×ÛºÏÕ÷ÏÔ΢Íâ¿ÆÖÎÁÆÁÆÐ§¡£·½·¨£º»¼Õß¾ùÐÐÉñ¾ÏµÍ³¼ì²éºÍMRI¼ì²é£¬²¢¾ÏÔ΢Íâ¿ÆÊÖÊõÖÎÁÆ¡£ÊÖÊõǰºóÏàÓ¦µØÓ¦ÓÃÄò¶¯Á¦Ñ§£¬Éñ¾µçÉúÀíµÈ¼ì²éÊֶΡ£ÊõºóÁÆÐ§¸ù¾ÝHoffman¹¦ÄÜÐÔ·Ö¼¶¡¢KirollosÊõÖÐËɽâ·Ö¼¶¡¢Äò¶¯Á¦Ñ§ºÍÉñ¾µçÉúÀíµÈ½á¹û½øÐÐÆÀ¶¨¡£½á¹û£º¸ù¾ÝHoffman¹¦ÄÜÐÔ·Ö¼¶£ºÊõºóÎÞÖ¢×´87Àý(14.2%)£¬Çá¶ÈÀý(47.3%)£¬ÖжÈÀý(35.1%)£¬ÖضÈ21Àý(3.4%)¡£°´KirollosÊõÖÐËɽâ·Ö¼¶ÆÀ¶¨·½·¨£ºÀý(96.0%)´ïµ½¢ñ¼¶£¬16Àý(2.6%)´ïµ½¢ò¼¶£¬8Àý(1.3%)Ϊ¢ó¼¶¡£Äò¶¯Á¦Ñ§¼ì²éÔÚÊõǰºÍÊõºóÓÐÏÔÖøÐÔ²îÒì¡£Éñ¾µçÉúÀí¼ì²éÔÚÊõǰºÍÊõºóÓÐÏÔÖøÐÔ²îÒì¡£½áÂÛ£ºÏÔ΢Íâ¿ÆÊÖÊõÖÎÁÆÖ¬·¾ÁöÐͼ¹Ëè˩ϵ×ÛºÏÕ÷¿É»ñµÃ½ÏºÃµÄÁÆÐ§£¬Äò¶¯Á¦Ñ§ÒÔ¼°Éñ¾µçÉúÀíµÄÁÙ´²Ó¦ÓÿÉÒÔÌá¸ß¼¹Ëè˩ϵ×ÛºÏÕ÷µÄÖÎÁÆÁÆÐ§¡£
¡¡¡¡Ö¬·¾Áö;¼¹Ëè˩ϵ;ÏÔ΢ÊÖÊõ;Éñ¾µçÉúÀí;Äò¶¯Á¦Ñ§
¡¡¡¡ThecurativeeffectofLipomaTetheredcordsyndromemicrosurgerytreatment:Reportofcases
¡¡¡¡Cui-zhiqiangXiubo*XiaokaiSun-zhenxingDuan-hongyuLuo-tianbao
¡¡¡¡Dept.ofSpinalcordAndSpianalcolumnNeurosurgery,Beijing()
¡¡¡¡[Abstract]Objective:TodiscusstherapeuticeffectofmicrosurgerytreatmentofLipomaTetheredcordsyndromebyanalyzingtheclinicaldataofcases.Method:ExaminationsinnervoussystemandMRIwereconducted.ThemicrosurgicaltreatmentofLipomaTetheredcordsyndromewasperformedinallcasesandthetherapeuticeffectivenessafteroperationwasanalyzedaccordingtoHoffmangradingsystem,Kirollosgradingsystem,urodynamicalexaminationandelectrophysiologicalexaminationinthepatients.Result:AccordingtoHoffmangradingsystem,87patientswereasymptomatic,mild,moderateand21severe.ThedegreeofuntetheringatmicrosurgerywhichisbasedonKirollosgradingsystemisassessed:Grade¢ñincases(96.0%),Grade¢òin16cases(2.6%),Grade¢óin8cases(1.3%).Recentcurativeeffectivenessinpatientswasrecorded,amongthem89cases(14.6%)excellent,cases(62.4%)effective£¬cases(22.3%)notchangedand5case(0.98%)aggravated.Therewassignificantdifferenceinurodynamicalexaminationbetweenpresurgeryandpostsurgery.Therewassignificantdifferenceinelectrophysiologicalexaminationbetweenpresurgeryandpostsurgery.Conclusion:ItisachievedthemutualrecognitionthatTetheredcordsyndromeistreatedassoonaspossiblebythemicrosurgerysurgery.ClinicalpracticeofurodynamicsaswellastheneuroelectricityphysiologymayenhancecurativeeffectofLipomaTetheredcordsyndrome,
¡¡¡¡[Keywords]Lipoma;Tetheredcordsyndrome;Microsurgery;Electropysiology;Urodynamics
¡¡¡¡¼¹Ëè˩ϵ×ÛºÏÕ÷(Tetheredcordsyndrome,TCS)ÊÇÓÉÓÚ¸÷ÖÖºóÌìºÍÏÈÌìÔÒòÇ£ÀÔ²×¶,Ôì³É¼¹Ëè´«µ¼ÊøÒÔ¼°µÍλÖÐÊಡ±ä£¬²¢²úÉúһϵÁÐÉñ¾¹¦ÄÜÕϰµÄÖ¢ºòȺ[1,2]¡£Ö¬·¾ÁöÐÍTCSÊÇÆäÖбȽÏÌØÊâµÄÒ»ÖÖÀàÐÍ£¬±íÏÖΪ¼¹ÖùÁѼ°¼¹Ë輹ĤÅò³ö°é·¢Ö¬·¾Áö£¬Ö¬·¾Áö×éÖ¯ÓëÔ²×¶¡¢Ñü÷¾Éñ¾¼°ÖÕË¿¹ã·ºÕ³Á¬,½»Ö¯´í¹¹Éú³¤[2]¡£ÕâÐ©ÌØµã¾ö¶¨ÁËÊÖÊõµÄ·çÏոߣ¬ÈÝÒ×ËðÉËÉñ¾£¬ÊõºóÈÝÒ×ÔÙ˩ϵ£¬ÁÆÐ§²îÒì½Ï´ó¡£±¾ÎľÍÎÒÔºÉñ¾Íâ¿ÆÄê6ÔÂÖÁÄê12ÔÂÊÕÖεÄÀýÖ¬·¾ÁöÐÍTCS£¬·ÖÎöÆäÏÔ΢ÊÖÊõÖÎÁƵÄÁÆÐ§¡£
¡¡¡¡×ÊÁϺͷ½·¨
¡¡¡¡1¡¢Ò»°ã×ÊÁÏ
¡¡¡¡±¾×éÀýÖ¬·¾ÁöÐÍTCS£¬ÆäÖÐÓÐÐ§Ëæ·ÃÀý(Ëæ·ÃÂÊ88.0%)¡£ÄÐÐÔÀý(50.4%)£¬Å®ÐÔÀý(49.6%)¡£ÄêÁä6Сʱ¡«73Ë꣬ƽ¾ùÄêÁä13.9Ëê¡£ÆäÖÐÐÂÉú¶ù(³öÉúÖÁ1¸öÔÂ)31Àý(5.1%)£¬Ó¤¶ù(СÓÚ1ÖÜËê)94Àý(15.4%)£¬1Ëê¡«60ËêÀý(77.6%)£¬60ËêÒÔÉÏ12Àý(1.9%)¡£
¡¡¡¡2¡¢Êõǰ·ÖÎö
¡¡¡¡¢ÙÁÙ´²±íÏÖ£º²ÎÕÕHoffmanµÈ[3]Ö¬·¾¼¹Ë輹ĤÅò³ö¹¦ÄÜÐÔ·Ö¼¶£¬½«¼¹Ëè˩ϵ֢״·ÖΪÎÞÖ¢×´¡¢Çá¡¢ÖС¢ÖØËĶȡ£Çá¶È±íÏÖΪÅÅÄò»ù±¾Ë³³©Å¼ÓÐÁÜÀì²»¾¡£¬´ó±ãż¸ÉÔÎÞ×ã»ûÐΣ¬ÎÞÏÂÖ«¼¡Á¦Ï½µ;ÖжȱíÏÖΪÅÅÄò²»³©£¬ÁÜÀì²»¾¡£¬´ó±ãʱ³£¸ÉÔ×ãÄÚ·»ûÐΣ¬ÎÞ»òÇá¶ÈÏÂÖ«¼¡ÈâήËõ£¬ÄÜÐÐ×ß;ÖØ¶È±íÏÖΪÅÅÄò²»³©£¬ÁÜÀì²»¾¡£¬ÓÐÄòäóÁô£¬´ó±ã¸ÉÔÅűãÀ§ÄÑ£¬×ãÃ÷ÏÔÄÚ·»ûÐΣ¬ÏÂÖ«¼¡ÈâÃ÷ÏÔήËõ£¬ÐÐ×ßÀ§ÄÑ¡£
¡¡¡¡¢Ú¸¨Öú¼ì²é
¡¡¡¡MRI±íÏÖ£ºËùÓл¼Õß¾ùÐÐMRI¼ì²é£¬¸ù¾ÝÓ°Ïñ±íÏÖ·ÖΪÖÕË¿ÐÍ¡¢Ô²×¶ÅÔÐÍ(°üÀ¨±³²àºÍ¸¹²à)ºÍÖ¬·¾¼¹Ë輹ĤÅò³öÐÍ[7-9]¡£
¡¡¡¡Äò¶¯Á¦Ñ§¼ì²é£º±¾×éÀýÖÐÀýÐÐÊõǰÊõºóÅÔë××î´óÈÝ»ýºÍ²ÐÓàÄòÁ¿µÄB³¬¼ì²é£¬ÒÔ²ÐÓàÄòÁ¿±ä»¯×÷Ϊһ¸öÖ¸±êÅжÏÊõºóÁÆÐ§¡£±¾×éÀýÖÐÀýÍê³ÉÊõǰÊõºóµÄÄò¶¯Á¦Ñ§¼ì²é¡£
¡¡¡¡Éñ¾µçÉúÀí¼ì²é£º±¾×éÀýÖÐÀýÊõǰÊõºóÉñ¾µçÉúÀí¼ì²â£¬Èý¸öÖ¸±êÕý³£Öµ·Ö±ðÊÇ£ºÓÕ·¢µç벨·ù7.21mv¡À4.77mv;DZ·üÆÚ3.25ms¡À0.45ms;´«µ¼ËÙ¶È50.57m/s¡À4.42m/s¡£
¡¡¡¡3¡¢ÊÖÊõ·½Ê½
¡¡¡¡²ÉÓúóÕýÖÐÖ±ÇпÚÈë·£¬Ã÷ÏÔÅò¡µÄÖ¬·¾°ü¿é×ÝÏòËóÐÎÇпڡ£ÑØÕýÖаþ¿ªÁ½²à×µÅÔ¼¡,ÏÔ¶׵°åºÍ¼¬Í»È±Ë𴦡£À©´ó×µ°åÇгýÖÁÕý³£Ó²Ä¤,Ϊ¼õÉÙÊÖÊõ¶Ô¼¹Ëè¼°Éñ¾¸ùµÄÇ£À,ÇпªÓ²¼¹Ä¤ºóÏÈÐÐÖ¬·¾ÁöÄÒÄÚÇгý,×îºóÓÎÀë°üĤ,̽²éӲĤÄÒÁ½²à,ÈñÐÔÓÎÀëӲĤÄÒÁ½²àµÄÕ³Á¬,ËɽâÕ³Á¬µÄ¼¹Éñ¾¡£Ó¦²ÉÓÃÉñ¾°þÀë×ӷִΡ¢Ð¡¿éÈ¥³ýÁöÌåÄÚÖ¬·¾×éÖ¯£¬ÊõÖвÉÓõç´Ì¼¤Æ÷£¬·Ö±æÏËÎ¬Êø´øºÍÉñ¾¡£¾¡¿ÉÄܱ£³ÖÊõÒ°ÄÚ¡°ÎÞѪ¡±×´Ì¬£¬²¢ÓÃÈ˹¤Ó²¼¹Ä¤ÐÞ²¹Ó²Ä¤£¬·ÀÖ¹ÊõºóÖëÍøÄ¤ÏÂǻճÁ¬ÔÙ˩ϵ¡£
¡¡¡¡ÁíÍ⣬¶ÔÓÚÉöÓÛ»ýË®»¼ÕßÊõºó¾ù²ÉÈ¡¼äЪÐÔÇå½àµ¼Äò£¬Õë¶ÔÏÂÖ«¼¡ÈâήËõ»¼Õß¾ùÖ¸µ¼Æä¿µ¸´ÖÎÁÆ¡£Õë¶Ô×㲿Çá¶È»ûÐÎÖ¸µ¼Æä´©½ÃÐÎЬ¡£
¡¡¡¡4¡¢Ëæ·Ã
¡¡¡¡ËùÓл¼Õß½øÐе绰»òÃÅÕïËæ·Ã£¬¸ù¾ÝËæ·ÃÄÚÈÝÅж¨ÊÖÊõÁÆÐ§£¬¾ßÌå°üÀ¨£º
¡¡¡¡ÁÙ´²±íÏÖ£º²ÎÕÕHoffmanµÈÖ¬·¾¼¹Ë輹ĤÅò³ö¹¦ÄÜÐÔ·Ö¼¶£¬·ÖÎöÊõǰÊõºó¸ÄÉÆÇé¿ö¡£
¡¡¡¡°´Kirollos[2]ÊõÖÐ˩ϵËɽâ·Ö¼¶ÆÀ¶¨·¨À´ÆÀ¶¨Ëɽâ³Ì¶È,¢ñ¼¶:ËùÓÐÒýÆð¼¹Ëè˩ϵµÄÒòËØ¾ùÏûʧ;¢ò¼¶:²¿·ÖËɽâ;¢ó¼¶:Ëɽâδ³É¹¦¡£
¡¡¡¡Äò¶¯Á¦Ñ§½á¹û±ê×¼[7£¬8]£º×î´ó°òë×ÈÝÁ¿Îª»¼¶ù³öÏÖÇ¿ÁÒÄòÒâ»ò³öÏÖ©ÄòʱµÄ°òë×ÈÝÁ¿;ÔÚ³äÓ¯ÆÚ£¬°òë×ѹÁ¦Ê¼ÖÕά³ÖÔÚ15cmH2O£¬Èç°òë×ÈÝÁ¿±ä»¯ÖµÓë±ÆÄò¼¡Ñ¹Á¦±ä»¯ÖµÖ®±È30ml/cmH2OΪ˳ӦÐÔ½µµÍ;»¼ÕßÔÚ°òë׳äÓ¯ÆÚ³öÏÖ×Ô·¢»òÓÕ·¢µÄ²»ÄÜÒÖÖÆµÄÆÚÏàÐÔѹÁ¦¡Ý15ml/cmH2OΪ±ÆÄò¼¡·´É俺½ø;ÅÅÄòÆÚ±ÆÄò¼¡ÊÕËõ²»ÄÜÅſհòë×ÇÒÎÞÄòµÀÍâÀ¨Ô¼¼¡µÄÊÕËõΪ±ÆÄò¼¡ÎÞÁ¦;±ÆÄò¼¡ÊÕËõʱ³öÏÖÄòµÀÍâÀ¨Ô¼¼¡µÄʱÏàÊÕËõ¶øµ¼ÖÂÅÅÄòѹÔö¸ß¡¢ÄòÁ÷¼ä¶ÏΪ±ÆÄò¼¡À¨Ô¼¼¡²»Ðµ÷¡£
¡¡¡¡Éñ¾µçÉúÀí£ºëÖºóÉñ¾MCV¼à²âµÄ½á¹ûÓÐÀûÓÚÅжÏÊÖÊõЧ¹û¼°Éñ¾¹¦ÄÜ¿ÉÄָܻ´µÄ³Ì¶È[9]¡£
¡¡¡¡²¢·¢Ö¢£ºÍ¨¹ýÓë´ó×Ú²¡Àýͳ¼Æ½á¹û¶Ô±È£¬ÅжÏÊÖÊõÁÆÐ§¡£
¡¡¡¡5¡¢Í³¼ÆÑ§·½·¨
¡¡¡¡¶Ô¼ÆÁ¿×ÊÁϰüÀ¨°òëײÐÓàÄòÁ¿¼°ëÖÉñ¾µçÉúÀí²â¶¨½á¹ûÀûÓöÀÁ¢Ñù±¾t¼ìÑé½øÐбȽÏ;¶Ô¼ÆÊý×ÊÁϰüÀ¨ÁÙ´²±íÏÖºÍÄò¶¯Á¦Ñ§¼ì²é½á¹ûÀûÓöÀÁ¢Ñù±¾¦Ö2¡¢Ð£Õý¦Ö2»òFisherÈ·ÇиÅÂÊ·¨±È½Ï¡£SPSS16.0·ÖÎö´¦ÀíÊý¾Ý£¬¼ìÑéË®×¼P0.05ΪÓÐÒâÒå¡£
¡¡¡¡½á¹û
¡¡¡¡1¡¢ÁÙ´²±íÏÖÁÆÐ§:²ÎÕÕHoffmanµÈÖ¬·¾¼¹Ë輹ĤÅò³ö¹¦ÄÜÐÔ·Ö¼¶£¬±¾×鲡ÀýÖУºÊõǰ¼°ÊõºóÖ¢×´¸Ä±ä¼û±í1£¬Í³¼Æ½á¹ûÌáʾÎÞÖ¢×´¡¢Çá¶È¼°ÖжÈÖ¢×´µÄ»¼ÕßÊõǰ¡¢ÊõºóÓÐÃ÷ÏÔ²îÒ죬¶øÖضÈÖ¢×´µÄ»¼ÕßÊõǰ¡¢Êõºó¼äÎÞÃ÷ÏÔ²îÒì¡£
¡¡¡¡2¡¢°´KirollosÊõÖÐ˩ϵËɽâ·Ö¼¶ÆÀ¶¨·½·¨:Àý(96.0%)´ïµ½¢ñ¼¶,16Àý(2.6%)´ïµ½¢ò¼¶,8Àý(1.3%)Ϊ¢ó¼¶¡£
¡¡¡¡3¡¢MRI±íÏÖ£ºÔ²×¶Î»ÖþùλÓÚL2×µÌåÆ½ÃæÒÔÏÂ,ÆäÖÐÖÕË¿ÐÍÀý(23.0%),Ô²×¶ÅÔÐÍÀý(42.1%)£¬Ö¬·¾Áö¼¹Ë輹ĤÅò³öÐÍÀý(34.9%)¡£Í¼1ΪһÀýÔ²×¶ÅÔÐ͵ÄÊõǰ¼°ÊõºóMRIÓ°Ïñ¡£Í¼2ΪÖÕË¿ÐͺÍÖ¬·¾Áö¼¹Ë輹ĤÅò³öÐ͵ÄʾÒâͼ¡£
ͼ1.¼¹ËèÖ¬·¾ÁöÊõǰÊõºó
¡¡×¢£º×óͼʾT11-L3½Ú¶Î×µ¹ÜÄÚÖ¬·¾Áö(Ô²×¶ÅÔÐÍ);ÓÒͼʾ֬·¾Áö´ó²¿ÇгýÊõºó¸Ä±ä¡£
ͼ2.ÖÕ˿֬·¾ÁöʾÒâͼ֬·¾ÁöÐͼ¹Ë輹ĤÅò³öʾÒâͼ
¡¡4¡¢ÊÖÊõǰºó°òë×B³¬£ºÊÖÊõǰºó²ÐÓàÄòÁ¿±ä»¯¼û±í2£¬Í³¼Æ½á¹ûÌáʾ¸÷ÄêÁä×éÖÐÊõǰ¡¢ÊõºóµÄ°òëײÐÓàÄòÁ¿ÓÐÃ÷ÏÔ²îÒì¡£
¡¡¡¡ÉöÔàB³¬¼ì²éʾÉöÓÛ»ýË®Àý(17.0%)£¬Êõºó¾¼äЪÐÔµ¼Äò3Ô¡«6ÔºóB³¬¼ì²éʾ£ºÍêÈ«Ïûʧ89Àý(85.6%)£¬¼õÉÙ10Àý(9.6%)£¬²»±ä4Àý(3.8%)£¬Ôö¼Ó0Àý£¬×Ü»º½âÂÊ´ï95.2%¡£±¾×éÀýÖÐÀýÍê³ÉÊõǰÊõºóµÄÄò¶¯Á¦Ñ§¼ì²é(¼û±í3)£¬Í³¼Æ½á¹ûÌáʾ²ÐÓàÄòÔö¶à¼°±ÆÄò¼¡ÎÞÁ¦ÔÚÊõǰ¡¢Êõºó¼äÓÐÃ÷ÏÔ²îÒ죬ÇÒÄò¶¯Á¦Ñ§ÔÚÊõºóÓÐÃ÷ÏÔ¸ÄÉÆ¡£
¡¡¡¡5¡¢±È½ÏëÖºóÉñ¾ÊõǰºÍÊõºóµÄÓÕ·¢µç벨·ù¡¢Ç±·üÆÚ¼°´«µ¼ËÙ¶ÈÈý¸öÖ¸±ê¡£¸ù¾ÝÊÖÊõǰºóͳ¼Æ±È½Ï(¼û±í4)£¬½á¹ûÌáʾëÖºóÉñ¾µçÉúÀí¼ì²âÖ¸±êÔÚÊõǰ¡¢Êõºó¼äÓÐÃ÷ÏÔ²îÒì¡£
¡¡¡¡6¡¢Êõºó²¢·¢Ö¢£ºÔÚ±¾×鲡ÀýÖÐÊõºó³öÏÖÍ·Í´Àý(29.1%);Éñ¾Ëðº¦5Àý(0.8%);ÄÔ¼¹ÒºÂ©¼ÙÐÔÄÒÖ×21Àý(3.4%);¸ÐȾ25Àý(4.1%);ÔÙ˩ϵ29Àý(4.7%)¡£
¡¡¡¡ÌÖÂÛ
¡¡¡¡¼¹ËèÖ¬·¾ÁöÊÇÔÚÉñ¾¹ÜÈÚºÏ֮ǰ(Ô¼ÂÑ×ÓÊܾ«ºó17Ìì¡«28Ìì)£¬ÒòijЩÖ»ûÒòËØÊ¹±íƤÍâÅß²ã¹ýÔçµØÓëÉñ¾ÍâÅß²ã·ÖÀ룬µ¼Ö¼äÖÊϸ°û½øÈëµ½Éñ¾°åµÄÊÒ¹ÜĤ±íÃæ²¢·Ö»¯ÐγÉÖ¬·¾£¬×îÖÕ¶Ô¼¹ËèÉñ¾·¢Óý²úÉúΣº¦¡£Ä¿Ç°¶Ô¼¹ËèÖ¬·¾Áö·ÖÐÍÈÔÓÐÕùÒ飬¸ù¾ÝMRI±íÏÖ½«Æä·ÖΪÖÕË¿ÐÍ¡¢Ô²×¶ÅÔÐÍ(°üÀ¨±³²àºÍ¸¹²à)ºÍÖ¬·¾¼¹Ë輹ĤÅò³öÐÍ[7¡«9]¡£±¾×鲡Àý£ºÖÕË¿ÐÍÕ¼23%,Ô²×¶ÅÔÐÍÕ¼42.1%£¬Ö¬·¾Áö¼¹Ë輹ĤÅò³öÐÍÕ¼34.9%¡£Ô²×¶±³²àÐÍ¡¢ÖÕË¿Ðͼ°Ö¬·¾Áö¼¹Ë輹ĤÅò³öÐÍ´¦ÀíÆðÀ´Ïà¶ÔÈÝÒ×;¶øÔ²×¶¸¹²àÐÍÒÔ¼°Óë¼¹Ëè»ìºÏÉú³¤µÄÖ¬·¾Áö£¬ÒòÒ»²à»ò/ºÍË«²àÉñ¾¸ù½øÈëÖ¬·¾ÁöÖУ¬Çгý·Ç³£À§ÄÑ£¬´ËʱʹÓÃÍâ¿Æ³¬ÉùÎüÒýÆ÷È黯֬·¾¿ÅÁ£,ÔÚ²»ËðÉ˸¹²àÉñ¾°åǰÌáÏÂ,´ó²¿·ÖÖ¬·¾Áö×éÖ¯¿É±»Îü³ö¡£
¡¡¡¡¸ù¾ÝHoffman·Ö¼¶µÄͳ¼Æ½á¹û£¬¿ÉÈÏΪÎÞÖ¢×´¼°Çá¶ÈÖ¢×´µÄ»¼ÕßÊõºóÁÆÐ§½ÏÂúÒ⣬¶øÖضÈÖ¢×´ÊõºóÁÆÐ§½Ï²î£¬¿ÉÄÜÖØ¶È֢״Ԥʾ×ÅÉñ¾²»¿ÉÄæÐÔËðÉË¡£Òò´Ë£¬´ÓÁÙ´²Ö¢×´½Ç¶ÈÀ´½²½¨Ò黼Õß¾¡ÔçÊÖÊõ£¬ÒÔ»ñµÃ½ÏºÃµÄÁÆÐ§¡£
¡¡¡¡Ö¬·¾Áö¶Ô¼¹ËèËðÉ˰üÀ¨¶Ô¼¹ËèµÄ¿¨Ñ¹ºÍ¶Ô¼¹ËèµÄÇ£À£¬Òò´ËÖÎÁƵÄÄ¿µÄÊÇÔÚ²»ËðÉ˼¹ËèºÍÉñ¾µÄͬʱʹ¼¹Ëè´ïµ½ÍêÈ«Ëɽ⣬ÍêÈ«½â³ý¼¹ËèѹÆÈ£¬²¢ÇÒӲĤÀ©´óÐÞ²¹ºó£¬ÔÚ÷¾¹ÜΪ¼¹Ë轨Á¢Ò»¸ö¿íËÉ×ÔÓÉÉÏÉý¿Õ¼ä£¬Ä¿Ç°¿ÉÈÏΪËɽâ³Ì¶È¾ö¶¨ÊÖÊõµÄÁÆÐ§¡£°´KirollosÊõÖÐ˩ϵËɽâ·Ö¼¶ÆÀ¶¨£¬±¾×鲡ÀýÖÐ96%´ïµ½¢ñ¼¶Ëɽ⣬´Ó½âÆÊµÄÒâÒåÉϽ²´ïµ½ÖÎÓú±ê×¼£¬¶øËɽâδ³É¹¦½öÕ¼1.3%¡£ÎÒÃǵÄÊÖÊõÌå»áÊÇ£º¢ÙÏÔ΢²Ù×÷,ÄæÏò°þÀë;¢ÚÓÐЧµÄÊõÖÐ¼à»¤ÌØ±ðÖØÒª[10£¬11£¬12]£ºÌرðÊÇÊõÖй۲ìÊÖÊõ´Ì¼¤Ê±ÏÂÖ«¼¡ÈâÊÕËõÇé¿öºÍÉñ¾µçÉúÀí¼à²â;¢ÛÑϸñÕÆÎÕÊÖÊõ³ß¶È£ºÊÖÊõÒÔ½â³ý¼¹ËèѹÆÈΪÖ÷Çв»¿É¹ý¶à²Ù×÷Ôì³É¹¦ÄܽøÒ»²½Ï½µ£¬±ÈÈçÓöµ½£º¢ÙÊÖÊõ·ÖÀëÒì³£À§ÄÑ;¢ÚÊõǰÉñ¾¹¦ÄÜËðº¦ÒѱȽÏÑÏÖØµÄ»¼Õß;¢ÛÔ²×¶¸¹²àÐÍÒÔ¼°¸´ºÏÐÍÖ¬·¾Áö£¬Ö¬·¾ÁöλÖÃÉ´í¹¹¸´ÔÓ£¬Éñ¾¸ù½øÈëÖ¬·¾ÁöÖС£
¡¡¡¡Äò¶¯Á¦Ñ§¼ì²é¿É¿Í¹Û·´Ó³TCSÉñ¾Ô´ÐÔ°òë×ÄòµÀ¹¦ÄÜÕϰµÄÀàÐͺÍÑÏÖØ³Ì¶È,Äò¶¯Á¦Ñ§µÄ¸Ä±äÔçÓÚÁÙ´²Ö¢×´¡£TCSÉñ¾Ô´ÐÔ°òë×ÄòµÀ¹¦ÄÜÕϰµÄÀàÐÍÖ÷ҪΪ±ÆÄò¼¡ÎÞ·´ÉäºÍµÍ˳ӦÐÔ°òë×£¬Õ¼50%,ÆäÖз¢ÉúÉö»ýË®»òÉö¹¦ÄÜËðº¦ÕßÕ¼83%[14]¡£±¾×黼Õß°´B³¬·ÖÎö½á¹û£¬¿ÉÈÏΪÊõºóÓаòëײÐÓàÄòµÄ»¼ÕßÃ÷ÏÔ¼õÉÙ(ÓÉ75.0%½µµ½41.1%)£¬±ÆÄò¼¡ÎÞÁ¦»¼ÕßÃ÷ÏÔ¼õÉÙ(ÓÉ70.6%½µµ½30.8%)£¬ÁíÍâÉöÓÛ»ýË®×Ü»º½âÂÊ´ï95.2%¡£ÑîÒÙµÈÈËÔÚÎÄÕÂÖÐÌá³ö32ÀýÖ¬·¾ÁöÐͼ¹Ëè˩ϵ²¡ÈËÊõºóÄòʧ½û¸ÄÉÆÂÊΪ15.6%£¬Êõºó±ÆÄò¼¡·´É俺½øÕ¼56.3%£¬±¾×é68Àý»¼ÕßÖÐÊõºó±ÆÄò¼¡·´É俺½øÕ¼4.4%£¬½ÏÖ®Ã÷ÏÔΪµÍ¡£
¡¡¡¡±¾×黼Õßͳ¼Æ½á¹ûÏÔʾ£¬ëÖÉñ¾µçÉúÀí¼ì²âÖ¸±êÔÚÊõºóÓÐÃ÷ÏÔ¸ÄÉÆ¡£¿ÉÈÏΪ£º¢ÙÔÚÊõÖеçÉúÀí¼ì²âÏÂÉñ¾²»»áËðÉË;¢ÚÖ»ÒªÉñ¾·¢Éú´«µ¼×èÖÍ˵Ã÷Ëæ×ż¹Ëè´úлÕϰµÄ³ÖÐø,Öð½¥ÀÛ¼°ÖáÍ»,³¤ÆÚÉñ¾Ê§ÓòúÉú¾ÖÔîÐÔÍÑËèÇÊ,ÊDz»¿ÉÄæ£¬¼ä½Ó˵Ã÷ÔçÆÚÊÖÊõµÄÖØÒªÐÔ[13]¡£
¡¡¡¡²¢·¢Ö¢£º´ó×Ú²¡Àýͳ¼ÆÊõºóÍ·Í´Æä·¢ÉúÂʿɴï43.7%[15]£¬Éñ¾Ë𺦼ÓÖØ·¢ÉúÂÊ5%¡£ÄÔ¼¹ÒºÂ©ºÍ¼ÙÐÔ¼¹Ä¤Åò³öµÄ·¢ÉúÂÊΪ4%¡«10%[16,17],ÔÙ˩ϵ·¢ÉúÂÊΪ5%¡«33%[20,21]¡£ÔÚ±¾×鲡ÀýÖÐÊõºó³öÏÖÍ·Í´29.1%;Éñ¾Ëðº¦0.8%;ÄÔ¼¹ÒºÂ©¼ÙÐÔÄÒÖ×3.4%;¸ÐȾ4.1%;ÔÙ˩ϵ4.7%¡£²¢·¢Ö¢µÄ³öÏÖÃ÷ÏÔÉÙÓÚ´ó×Ú²¡Àýͳ¼Æ¡£±ÊÕßÈÏΪ£ºÑÏÃÜ·ìºÏӲĤ;Ó¦ÓÃÉñ¾µçÉúÀíµÄÊõÖмà²â;×µÅÔ¼¡Èâ×ªÒÆ;·ìºÏÁ½²à¼¡½îĤ°ê²¢×÷ƤÏÂÒýÁ÷[18]ÒÔ¼°±£Áô²¿·ÖƤÏÂÖ¬·¾Áö[19]£¬ÕâЩ´ëÊ©´ó´óµØ½µµÍÁ˲¢·¢Ö¢µÄ·¢ÉúÂÊ£¬´ËÍâÀ©´óӲĤÄÒÈÝÄÉÄÔ¼¹Òº,ʹ¼¹ËèºÍÉñ¾¸ù×ÔÓɽþÅÝÔÚÄÔ¼¹ÒºÖÐ,ÓÐÀûÓÚ·ÀÖ¹ÔÙ˩ϵ[22]¡£
¡¡¡¡×ÜÖ®£¬ÏÔ΢Íâ¿ÆÊÖÊõÖÎÁÆÖ¬·¾ÁöÐͼ¹Ëè˩ϵ×ÛºÏÕ÷¿É»ñµÃ½ÏºÃµÄÁÆÐ§£¬ÓÈÆä½¨Ò黼Õß¾¡ÔçÊÖÊõ£¬ÒÔ·ÀÉñ¾µÄ½øÐÐÐÔËðÉË¡£ÁíÍ⣬Äò¶¯Á¦Ñ§ÒÔ¼°Éñ¾µçÉúÀíµÄÁÙ´²Ó¦ÓöԼ¹Ëè˩ϵ×ÛºÏÕ÷µÄÕïÁÆÓнϴóµÄ°ïÖú¡£
²Î¿¼ÎÄÏס¡¡¡[1]Ò×ÉùÓí.ÒþÐÔ¼¹ÖùÁÑÓë¼¹Ëè˩ϵ×ÛºÏÕ÷[A].¼û:ÍõÖÒ³ÏÖ÷±à.Éñ¾Íâ¿ÆÑ§[M].Î人:ºþ±±¿Æ¼¼³ö°æÉç,..
¡¡¡¡[2]KirollosRW,Van-HillePT.Evaluationofsurgeryforthetetheredcordsyndromeusinganewgradingsystem[J].BrJNerurosurg,,10(3):.
¡¡¡¡[3]HoffmanHJ,TaecholarnC,HendrickEB,etal.Managementoflipomyelomeningoceles.JNeurosurg,,62:1-8.
¡¡¡¡[4]Íõºã±ù,¹ù×ÚÔ¶,ÎâÈÙµÂ,µÈ.Ö¬·¾ÁöÐͼ¹Ëè˩ϵ×ÛºÏÕ÷µÄÊÖÊõ¸Ä½ø¼°ÁÆÐ§ÆÀ¼Û[J].ÖлªÐ¡¶ùÍâ¿ÆÔÓÖ¾,,25(5):-.
¡¡¡¡[5]ÍõÏܸÕ,ÖÜÓÀµÂ,¼ªÊ¿¿¡,µÈ.Ö¬·¾ÁöÐͼ¹Ëè˩ϵ×ÛºÏÕ÷µÄ²¡Àí¼°ÖÎÁÆ[J].ÖлªÐ¡¶ùÍâ¿ÆÔÓÖ¾,,16(4):-.
¡¡¡¡[6]AraiH,SatoK,OkudaO,etal.Surgicalexperienceofpatientswithlumbosacrallipomas[J].ActaNeurochir(Wien),,(9):-.
¡¡¡¡[7]ÑîÒÙ£¬Íõ࣬Íõ³¤ÁÖ£¬¼¹Ëè˩ϵ×ÛºÏÕ÷ÊõºóÄò¶¯Á¦Ñ§²â¶¨¼°ÁÙ´²ÒâÒå.ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾[J]£¬,25(9)£¬-.
¡¡¡¡[8]ÑîÓ£¬ÎâÊ¿Á¼£¬ÄÇÑåȺ£¬¼¹Ëè˩ϵ»¼ÕßµÄÄò¶¯Á¦Ñ§ÆÀ¹ÀºÍÖÎÁƶԲß.ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾[J]£¬,23(5)£¬-.
¡¡¡¡[9]ÀîÇ¿£¬Ê¯Ö¾²ÅÉñ¾µçÉúÀí¼¼ÊõÔÚ¼¹Ëè˩ϵ×ÛºÏÕ÷ÕïÖÎÖÐÓ¦ÓÃ.¼¹ÖùÍâ¿ÆÔÓÖ¾£¬,1(5):-.
¡¡¡¡[10]´Þ־ǿ£¬ÐÞ²¨µÈÀýÏÈÌìÐÔÉñ¾¹Ü»ûÐεÄÏÔ΢Íâ¿ÆÖÎÁÆ[J].¿Æ¼¼µ¼±¨.27(24)£º67-69.
¡¡¡¡[11]½ªºêÖ¾,ÑîÓñÃ÷,лºìö©,µÈ.¼¹Ëè˩ϵ×ÛºÏÕ÷µÄÏÔ΢ÊÖÊõÖÎÁÆ[J].ÖлªÍâ¿ÆÔÓÖ¾,,40:-.
¡¡¡¡[12]´Þ־ǿ£¬ÐÞ²¨£¬Ïô¿.¼¹Ëè˩ϵ×ÛºÏÕ÷ÀýÁÙ´²ÕïÁÆ·ÖÎö[J].ÖйúÒ½¿¯,,45(11):31-33.
¡¡¡¡[13]ÐÞ²¨,Áõ×Ú»Ý,»ÆºìÔÆ,µÈ.¼¹Ëè˩ϵ×ÛºÏÕ÷µÄÏÔ΢Íâ¿ÆÊÖÊõÖÎÁÆ[J].ÖлªÉñ¾Íâ¿ÆÔÓÖ¾,9,15(5):-.
¡¡¡¡[14]л¿Ë»ù£¬¼¹Ëè˩ϵ×ÛºÏÕ÷µÄÕïÖÎ.¹ã¶«Ò½Ñ§[J]£¬£¬26(5)£¬-
¡¡¡¡[15]¡¡SpiegelDA.Pediatricspinaldeformities[J].CurrOpinOrthop,,12:-.
¡¡¡¡[16]¡¡VanCalenberghF,VanvolsemS,VerpoortenC,eta.lResultsaftersurgeryforlumbosacrallipoma:thesignificanceofearlyandlateworsening[J].ChildsNervSyst,9,15:-.
¡¡¡¡[17]OheN,FutamuraA,KawadaR,eta.lSecondarytetheredcordsyndromeinspinaldysraphism[J].ChildsNervSyst,,16:-.
¡¡¡¡[18]¡¡Ê¯Ö¾²Å,Àî¼Ò˳,¼ÖÁ¬Ë³.¼¹Ëè˩ϵ×ÛºÏÕ÷µÄÑо¿ÏÖ×´[J].ÖлªÍâ¿ÆÔÓÖ¾,,33:-.
¡¡¡¡[19]´Þ־ǿ£¬ÐÞ²¨£¬Ïô¿.ÏÔ΢ÊÖÊõÖÎÁƼ¹Ë輹ĤÅò³öµÄÁÆÐ§¼°Ó°ÏìÒòËØ·ÖÎö(¸½Àý±¨¸æ)[J].±±¾©Ò½Ñ§,,45(11):31-33.
¡¡¡¡[20]¡¡PhuongLK,SchoeberlKA,RaffelC.Naturalhistoryoftetheredcordinpatientswithmeningomyelocele[J].Neurosurg,,50:-.
¡¡¡¡[21]¡¡BowmanRM,McLoneDG,GrantJA,eta.lSpinabifidaout ¡¡¡¡Èç¹ûÄú»¹ÐèÒª¸ü½øÒ»²½Á˽⣬Äú¿ÉÒÔµã»÷×óϽǡ°ÔĶÁÔÎÄ¡±ºÍÒ½ÉúÔÚÏß½»Á÷£¡
ÔÞÉÍ
³¤°´å“ªé‡Œæ²»ç™½ç™œé£Žç—?ç™½ç™œé£Žä¼ æŸ“é€”å¾„
×ªÔØÇë×¢Ã÷£ºhttp://www.twwaa.com/zldyz/6278.html